新型心肌损伤标志物的急诊应用研究进展

doi:10.3969/j.issn.1002-1949.2018.05.017

摘要
图/表
参考文献(55)
相关文章 (0)

全文: PDF (5457 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要随着胸痛中心建设的快速发展，人们对急诊胸痛患者越来越重视，如何使急诊胸痛患者得到及时、精确、个性化的治疗是急诊当前最大的挑战。超早期心肌损伤标志物是急诊胸痛诊断的重要组成部分。本文从炎症反应相关标志物、缺血相关性标志物、心力衰竭相关性标志物及微小核糖核酸（miRNA）等方面综述超早期新型心肌损伤标志物在急诊应用的研究进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄春才
	柴艳芬

关键词 ：心肌损伤标志物, 急诊胸痛, 胸痛中心

通讯作者: 柴艳芬（1965-），女，主任医师，教授，硕士生导师，E-mail: chaiyanfen2012@126.com。

作者简介: 黄春才（1983-），男，硕士研究生,住院医师，E-mail: 59863824@qq.com。

引用本文:

黄春才，柴艳芬. 新型心肌损伤标志物的急诊应用研究进展[J]. 中国急救医学, 2018, 38(5): 455-.
Huang Chun-cai,Chai Yan-fen. Research progress in old and new cardiac biomarkers in patients with acute chest pain. Chinese Journal of Critical Care Medicine, 2018, 38(5): 455-.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2018.05.017 或 http://www.cnemergency.org.cn/CN/Y2018/V38/I5/455

［1］Ladue JS, Wroblewski F, Karmen A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction［J］. Science, 1954, 120(3117):497-499. ［2］World Health Organization. Hypertension and coronary heart disease: Classification and Criteria for Epidemiological Studies, First Report of the Expert Committee on Cardiovascular Diseases and Hypertension［R］. Geneva： WHO, 1959. ［3］Panteghini M. Enzyme and muscle diseases［J］. Curr Opin Rheumatol, 1995, 7(6):469-474. ［4］Starr JW, Wagner GS, Draffin RM, et al. Vectorcardiographic criteria for the diagnosis of anterior myocardial infarction［J］. Circulation, 1976, 53(2):229-234. ［5］Gibler WB, Gibler CD, Weinshenker E, et al. Myoglobin as an early indicator of acute myocardial infarction［J］. Ann Emerg Med, 1987, 16(8):851-856. ［6］Rapaport E. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature［J］. Circulation, 1979, 59(3):607-609. ［7］Hamm CW, Katus HA. New biochemical markers for myocardial cell injury［J］. Curr Opin Cardiol, 1995, 10(4):355-360. ［8］Carlton EW, Cullen L, Than M, et al. A novel diagnostic protocol to identify patients suitable for discharge after a single high-sensitivity troponin［J］. Heart, 2015, 101(13):1041-1046. ［9］Weber M, Bazzino O, Navarro Estrada JL, et al. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome［J］. Am Heart J, 2011, 162(1):81-88.〖ZK)〗 ［10］Rodriguez F, Mahaffey KW. Management of Patients With NSTE-〖JP〗ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines［J］. J Am Coll Cardiol, 2016, 68(3):313-321. ［11］Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes［J］. Clin Chem, 2007, 53(10):1800-1807. ［12］Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial［J］. J Am Coll Cardiol, 2000, 35(6):1535-1542. ［13］Prabhu M. HS CRP IN ACUTE CORONARY SYNDROME［C］// Aace Meeting. 2016. ［14］Russell CJ, Exley AR, Ritchie AJ. Widespread coronary inflammation in unstable angina［J］. N Engl J Med, 2003, 348(19):1931. ［15］Govindarajan S, Raghavan VM, Rao AC. Plasma Myeloperoxidase and Total Sialic Acid as Prognostic Indicators in Acute Coronary Syndrome［J］. J Clin Diagn Res, 2016, 10(8):BC9-13. ［16］Dollery CM, Mcewan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease［J］. Circ Res, 1995, 77(5):863-868. ［17］Fingleton B. Matrix metalloproteinases as valid clinical targets［J］. Curr Pharm Des, 2007, 13(3):333-346. ［18］Fernandez MN, Gagliardi J, Fabre B, et al. Matrix metalloproteinases and psychosocial factors in acute coronary syndrome patients［J］. Psychoneuroendocrinology, 2016, 63:102-108. ［19］Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes［J］. Circulation, 2004, 108(9):1049-1052. ［20］Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes［J］. N Engl J Med, 2001, 345(14):1022-1029. ［21］Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain［J］. JAMA, 2004, 291(4):435-441. ［22］Cassidy A, Chiuve SE, Manson JE, et al. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women［J］. Arterioscler Thromb Vasc Biol, 2009, 29(1):134-139. ［23］Su D, Li Z, Li X, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease［J］. Mediators Inflamm, 2013, 2013:726 178. ［24］Sinha MK, Gaze DC, Tippins JR, et al. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention［J］. Circulation, 2003, 107(19):2403-2405. ［25］Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department［J］. Am Heart J, 2006, 152(2):253-262. ［26］Wu AH. The ischemia-modified albumin biomarker for myocardial ischemia［J］. MlO MedLab Obs, 2003, 35(6):36-38,40. ［27］Rathore V, Singh N, Rastogi P, et al. Correlation of Inflammatory Marker with Glycogen Phosphorylase BB (GPBB)in Patients of Acute Myocardial Infarction［J］. Int J Contem Med Res, 2017, 4(5):1122-1124. ［28］Lillpopp L, Tzikas S, Ojeda F, et al. Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome［J］. Am J Cardiol, 2012, 110(9):1225-1230. ［29］Oliver MF. Free fatty acids and acute coronary syndromes—the history［J］. QJM, 2011, 104(7):625-627. ［30］Zschiesche W, Kleine AH, Spitzer E, et al. Histochemical localization of heart-type fatty-acid binding protein in human and murine tissues［J］. Histochem Cell Biol, 1995, 103(2):147-156. ［31］Pyati AK, Devaranavadagi BB, Sajjannar SL, et al. Heart-Type Fatty Acid Binding Protein: A Better Cardiac Biomarker than CK-MB and Myoglobin in the Early Diagnosis of Acute Myocardial Infarction［J］. J Clin Diagn Res, 2015, 9(10):BC8-11. ［32］Kilcullen N, Viswanathan K, Das R, et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values［J］. J Am Coll Cardiol, 2007, 50(21):2061-2067. ［33］Packard CJ, O′Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group［J］. N Engl J Med, 2000, 343(16):1148-1155. ［34］Chambless LE, Folsom AR, Davis V, et al. Risk Factors for Progression of Common Carotid Atherosclerosis: The Atherosclerosis Risk in Communities Study, 1987-1998［J］. Am J Epidemiol, 2002, 155(1):38-47. ［35］Chung H, Kwon HM, Kim JY, et al. Lipoprotein-Associated Phospholipase A2 Is Related to Plaque Stability and Is a Potential Biomarker for Acute Coronary Syndrome［J］. Yonsei Med J, 2014, 55(6):1507-1515. ［36］Danne O, Mckel M, Lueders C, et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes［J］. Am J Cardiol, 2003, 91(9):1060-1067. ［37］de Lemos JA, Mcguire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease［J］. Lancet, 2003, 362(9380):316-322. ［38］Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death［J］. N Engl J Med, 2004, 350(7):655-663. ［39］Keller T, Tzikas S, Zeller T, et al. Copeptin Improves Early Diagnosis of Acute Myocardial Infarction［J］. J Am Coll Cardiol, 2010, 55(19):2096-2106. ［40］Mckel M, Searle J, Hamm C, et al. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study［J］. Eur Heart J, 2015, 36(6):369-376. ［41］Ago T, Sadoshima J. GDF15, a cardioprotective TGF-β superfamily protein［J］. Circ Res, 2006, 98(3):294-297. ［42］Kai CW, Kempf T. Growth differentiation factor 15 in heart failure: an update［J］. Curr Heart Fail Rep, 2012, 9(4):337-345. ［43］Kai CW, Kempf T, Bo L, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome［J］. Circulation, 2007, 116(14):1540-1548. ［44］Kosova EC, de Lemos JA, Jarolim P, et al. Abstract 16378: Growth Differentiation Factor-15 Independently Predicts 2 Year Mortality in Patients With Acute Coronary Syndrome: Observations From the A to Z Trial［J］. Circulation, 2014, 2014:130. ［45］Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure［J］. J Am Coll Cardiol, 2017, 68(13):1476. ［46］董浩, 安永强, 刘巍. 可溶性ST2在心力衰竭中的研究进展［J］. 中国循证心血管医学杂志, 2017, 9(8):1010-1012. ［47］Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction［J］. Circulation, 2004, 109(18):2186-2190. ［48］Eggers KM, Armstrong PW, Califf RM, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome［J］. Am Heart J, 2010, 159(5):788-794. ［49］Tolppanen H, Rivas-Lasarte M, Lassus J, et al. Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome［J］. Crit Care Med, 2017， 45（7）：e666-e673. ［50］Lisowska A, Knapp M, Tycińska A, et al. Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study［J］. Atherosclerosis, 2016, 246:309-317. ［51］George M, Shanmugam E, Srivatsan V, et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study［J］. Ther Adv Cardiovasc Dis, 2015, 9(5):275-284. ［52］Singsaas EG, Manhenke CA, Dickstein K, et al. Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction［J］. Cardiology, 2016, 134(4):398. ［53］Zhang WQ, Xie BQ. A meta-analysis of the relations between blood microRNA-208b detection and acute myocardial infarction［J］. Eur Rev Med Pharmacol Sci, 2017, 21(4):848-854. ［54］Adachi T, Nakanishi M, Otsuka Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction［J］. Clin Chem, 2010, 56(7):1183-1185. ［55］Gidlf O, Smith JG, Miyazu K, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction［J］. BMC Cardiovasc Disord,2013, 13:12.